drugset / Trial / NCT06979362

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

NCT06979362 ↗

Phase 2 Recruiting 200 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.

Timeline

Start
2025-06-27
Primary completion
2027-11-16
Completion
2028-07-25

Drugs

EvaluationDrugModalityDoseRoute
Subject CDR132L Antisense oligonucleotide — Intravenous

Indications